ArticleHemaSphere2025

Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population.

Paolo Ghia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.